1. Home
  2. CYCU vs TCRT Comparison

CYCU vs TCRT Comparison

Compare CYCU & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$0.87

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.87

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
TCRT
Founded
2017
1998
Country
United States
United States
Employees
74
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
6.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
CYCU
TCRT
Price
$0.87
$2.87
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
667.0K
13.3K
Earning Date
06-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.66
EPS
N/A
N/A
Revenue
N/A
$15,900,000.00
Revenue This Year
$8.92
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.67
52 Week High
$7.13
$5.48

Technical Indicators

Market Signals
Indicator
CYCU
TCRT
Relative Strength Index (RSI) 42.82 57.39
Support Level $0.79 $2.39
Resistance Level $1.08 $2.85
Average True Range (ATR) 0.07 0.18
MACD 0.01 0.06
Stochastic Oscillator 34.08 68.35

Price Performance

Historical Comparison
CYCU
TCRT

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: